Mr. Ken d'Entremont reports

MEDEXUS HOLDS ANNUAL MEETING OF SHAREHOLDERS AND ANNOUNCES ELECTION OF DIRECTORS

Medexus Pharmaceuticals Inc. held its virtual annual meeting of shareholders today. Medexus shareholders elected all nominees listed in Medexus's management information circular dated Aug. 9, 2023, as directors through the next annual meeting. Shareholders also voted in favour of the appointment of PricewaterhouseCoopers LLP as the company's auditor and in favour of resolutions amending the company's equity incentive compensation plan.

Detailed voting results for the election of directors are set out in the attached table.

       VOTING RESULTS FOR ELECTION OF DIRECTORS

Name                     For               Against    

Ken d'Entremont    99.40% (6,610,209)   0.60% (39,627)
Harmony Garges     99.43% (6,612,024)   0.57% (37,812)
Benoit Gravel      99.40% (6,610,199)   0.60% (39,637)
Michael Mueller    99.43% (6,612,024)   0.57% (37,812)
Stephen Nelson     99.39% (6,609,409)   0.61% (40,427)
Nancy Phelan       99.42% (6,611,224)   0.58% (38,612)
Menassie Taddese   99.39% (6,609,409)   0.61% (40,427)

Shareholders also cast 7,498,887 (99.55 per cent) votes for and withheld 33,641 (0.45 per cent) votes from the appointment of PricewaterhouseCoopers LLP as the company's auditor, and cast 6,567,139 (98.76 per cent) votes for and 82,697 (1.24 per cent) votes against the resolutions amending Medexus's equity incentive compensation plan. All proposals were therefore approved.

Final voting results on all matters voted on at the annual meeting will be filed with Canadian securities regulatory authorities at SEDAR+.

About Medexus Pharmaceuticals Inc.

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy and dermatology.

We seek Safe Harbor.